Literature DB >> 1568309

Aspartate aminotransferase, alanine aminotransferase, and glutathione transferase in plasma during and after sedation by low-dose isoflurane or midazolam.

A F Howie1, E Spencer, G J Beckett.   

Abstract

To assess the effect of prolonged administration of midazolam or isoflurane on hepatocellular integrity, we measured the concentrations of glutathione transferase (EC 2.5.1.18) B1 subunit and the activities of alanine aminotransferase (ALT; EC 2.6.1.2) and aspartate aminotransferase (AST; EC 2.6.1.1) in 40 patients who required long-term sedation with low-dose midazolam or isoflurane. Blood samples were collected before and 24 h after the start of the sedation and 0, 24, 72, 120, and 172 h after the last dose. ALT and AST activities did not change appreciably, but the glutathione transferase B1 concentration decreased significantly (P less than 0.03) at all times studied. The patients who received isoflurane and those who received midazolam showed no significant differences in any of the enzyme tests. We conclude that long-term sedation with midazolam or isoflurane is unlikely to affect hepatocellular integrity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568309

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  [Sedation concepts with volatile anaesthetics in intensive care: practical use and current experiences with the AnaConDa system].

Authors:  J Kompardt; K Schärff; K Kubosch; C Pohl; M Bomplitz; J Soukup
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

2.  Abnormal glutathione conjugation in patients with tyrosinaemia type I.

Authors:  T M Mulders; D J Bergman; B T Poll-The; G P Smit; D D Breimer; G J Mulder; M Duran; J A Smeitink
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

3.  Isoflurane for prolonged sedation in the intensive care unit; efficacy and safety.

Authors:  E M Spencer; S M Willatts
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.